Comorbidity, Treatment and Mortality: A Population Based Cohort Study of Prostate Cancer in PCBaSe Sweden

Berglund, Anders; Garmo, Hans; Tishelman, Carol; Holmberg, Lars; Stattin, P.; Lambe, Mats

doi:10.1016/j.juro.2010.10.061

Cited by 108 publications

(104 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Our 10-year other-cause mortality estimates by Charlson score are similar to other mixed-treatment samples of men with prostate cancer obtained from administrative data or chart abstraction, 3,4 and may appear high due to the inclusion of only men aged 66 years. To ensure that our findings were robust across all ages, we repeated our comparative effectiveness models in age subgroups and found that men with Charlson scores of 3 do not benefit from aggressive treatment, regardless of their age at the time of diagnosis.…”

Section: Reply To Charlson Score and Competing Mortalitysupporting

confidence: 64%

“…2 The subsequent suspension of power morcellator sales from Johnson & Johnson has increased concerns regarding the use of minimally invasive techniques for myomectomy and hysterectomy in cases of large uteri, thus potentially limiting the diffusion of minimally invasive procedures. 3 Two interesting points of the investigation by George et al 1 deserve to be addressed. The first is in regard to the cost-effectiveness and risk-to-benefit ratio between intraperitoneal morcellation of undiagnosed leiomyosarcoma and the execution of unnecessary open abdominal procedures in patients with leiomyomas.…”

Section: In-bag Morcellation For Presumed Myoma Retrieval At Laparoscopymentioning

confidence: 99%

See 1 more Smart Citation

Reply to Charlson score and competing mortality

Daskivich

Litwin

Saigal

2014

Cancer

View full text Add to dashboard Cite

Section: Reply To Charlson Score and Competing Mortalitysupporting

confidence: 64%

Section: In-bag Morcellation For Presumed Myoma Retrieval At Laparoscopymentioning

confidence: 99%

Reply to Charlson score and competing mortality

Daskivich

Litwin

Saigal

2014

Cancer

View full text Add to dashboard Cite

“…In May 2016, NPCR was linked to the Prescribed Drug Registry, the Patient Registry, the Cause of Death Register, the Longitudinal database on socioeconomic factors (acronym in Swedish LISA) and the Register of Total Population and Population changes to generate Prostate Cancer data Base Sweden (PCBaSe) RAPID. As previously described, Charlson Comorbidity Index (CCI) was calculated based on discharge diagnoses in the Patient Registry by use of 17 groups of diseases with each diagnosis assigned a specific weight (1, 2, 3 and 6) and the sum of these weights resulted in three levels of CCI: 0 for no comorbidity, 1–2 for mild to moderate, and 3+ for severe comorbidity 12, 13…”

Section: Methodsmentioning

confidence: 99%

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population‐based study

Tomic

Ventimiglia

Robinson

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Patients with high socioeconomic status (SES) have better cancer outcomes than patients with low SES. This has also been shown in Sweden, a country with tax‐financed health care aiming to provide care on equal terms to all residents. The association between income and educational level and diagnostics and treatment as outlined in national guidelines and prostate cancer (Pca) and all‐cause mortality was assessed in 74,643 men by use of data in the National Prostate Cancer Register of Sweden and a number of other health care registers and demographic databases. In multivariable logistic regression analysis, men with high income had higher probability of Pca detected in a health‐check‐up, top versus bottom income quartile, odds ratio (OR) 1.60 (95% CI 1.45–1.77) and lower probability of waiting more than 3 months for prostatectomy, OR 0.77 (0.69–0.86). Men with the highest incomes also had higher probability of curative treatment for intermediate and high‐risk cancer, OR 1.77 (1.61–1.95) and lower risk of positive margins, (incomplete resection) at prostatectomy, OR 0.80 (0.71–0.90). Similar, but weaker associations were observed for educational level. At 6 years of follow‐up, Pca mortality was modestly lower for men with high income, which was statistically significant for localized high‐risk and metastatic Pca in men with no comorbidities. All‐cause mortality was less than half in top versus bottom quartile of income (12% vs. 30%, p < 0.001) among men above age 65. Our findings underscore the importance of adherence to guidelines to ensure optimal and equal care for all patients diagnosed with cancer.

show abstract

“…As previously described, Charlson Comorbidity Index (CCI) was calculated based on discharge diagnoses in the Patient Registry by use of 17 groups of diseases with each diagnosis assigned a specific weight (1, 2, 3 and 6) and the sum of these weights resulted in three levels of CCI: 0 for no comorbidity, 1-2 for mild to moderate, and 31 for severe comorbidity. 12,13 Information on educational level, annual disposable income, and marital status was retrieved from the LISA database. Men were categorized according to the highest attained level of education, into low (<10 years mandatory school), intermediate (10-12 years high school), and high (university or college).…”

Section: Study Populationmentioning

confidence: 99%

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. A nationwide population-based study

Tomic¹,

Ventimiglia²,

David³

et al. 2018

European Urology Supplements

View full text Add to dashboard Cite

Patients with high socioeconomic status (SES) have better cancer outcomes than patients with low SES. This has also been shown in Sweden, a country with tax-financed health care aiming to provide care on equal terms to all residents. The association between income and educational level and diagnostics and treatment as outlined in national guidelines and prostate cancer (Pca) and all-cause mortality was assessed in 74,643 men by use of data in the National Prostate Cancer Register of Sweden and a number of other health care registers and demographic databases. In multivariable logistic regression analysis, men with high income had higher probability of Pca detected in a health-check-up, top versus bottom income quartile, odds ratio (OR) 1.60 (95% CI 1.45-1.77) and lower probability of waiting more than 3 months for prostatectomy, OR 0.77 (0.69-0.86). Men with the highest incomes also had higher probability of curative treatment for intermediate and high-risk cancer, OR 1.77 (1.61-1.95) and lower risk of positive margins, (incomplete resection) at prostatectomy, OR 0.80 (0.71-0.90). Similar, but weaker associations were observed for educational level. At 6 years of follow-up, Pca mortality was modestly lower for men with high income, which was statistically significant for localized high-risk and metastatic Pca in men with no comorbidities. All-cause mortality was less than half in top versus bottom quartile of income (12% vs. 30%, p < 0.001) among men above age 65. Our findings underscore the importance of adherence to guidelines to ensure optimal and equal care for all patients diagnosed with cancer.

show abstract

Comorbidity, Treatment and Mortality: A Population Based Cohort Study of Prostate Cancer in PCBaSe Sweden

Cited by 108 publications

References 134 publications

Reply to Charlson score and competing mortality

Reply to Charlson score and competing mortality

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population‐based study

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. A nationwide population-based study

Contact Info

Product

Resources

About